EBS

#3046
Emergent Biosolutions, Inc.
8.0600 USD
+0.37%
부문: 헬스케어
베이스: USD
수익 통화: USD
일일 변동 비율
8.0301
8.0750
년간 변동
7.7400
11.4600
일일 변동
+0.37%
월간 변동
+0.25%
6달 변화
-24.81%
년간 변동율
-24.81%
이전 종가
8.0300
시가
8.0575
저가
8.0301
High
8.0750
양
159
전체 차트 열기

Financials

개요 성명 통계
4분기 연간
  • Market Capitalization 417.2731 M
  • Employee 900
  • Founded 1998
  • CEO Robert G. Kramer Sr.Joseph C. Papa
  • Website www.emergentbiosolutions.com
  • Headquarter Delaware, United States
  • FIGI BBG000GW06J7
  • Industry 전문의약품 및 제네릭 의약품 제조업체
총매출
순이익
주당 순이익(기본 EPS)
총부채
잉여 현금 흐름
현금 및 현금성 자산
주가수익비율
13.29
주가매출액비율
0.94

Emergent BioSolutions Inc

Emergent BioSolutions Inc. is an American multinational specialty biopharmaceutical company headquartered in Gaithersburg, Maryland. It develops vaccines and antibody therapeutics for infectious diseases and opioid overdoses, and it provides medical devices for biodefense purposes. Among the company's products are the controversial BioThrax, the only anthrax vaccine licensed by the U.S. Food and Drug Administration and Narcan for the emergency treatment of opioid overdose. The company also manufactures pharmaceuticals for infectious diseases like cholera and typhoid. During the COVID-19 pandemic, Emergent BioSolutions also produced Johnson & Johnson/Janssen and Oxford–AstraZeneca vaccines at one of its plants; however, this was marked by contamination and other production issues, and millions of doses of vaccine had to be discarded.

뉴스